Anti-PD-L1 Antibody-Drug Conjugates for Tumor Cell Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy treatments for cancers expressing PD-L1, such as melanoma, are inadequate, with a need for improved therapies to enhance T cell immune response and improve survival rates.
Innovation Solution
Development of novel anti-PD-L1 antibodies and antibody-drug conjugates, including PD-L1-directed camptothecin and MMAE ADCs, with specific binding affinities and internalization properties, to target and kill PD-L1-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-PD-L1 antibodies are used for immunotherapy, then T cell immune response is activated, but binding affinity and internalization are insufficient for optimal cancer cell killing
Solution Approach 1:
The patent modifies the binding affinity parameter of anti-PD-L1 antibodies by introducing specific amino acid substitutions in the complementarity-determining regions (CDRs). This results in antibodies with optimized binding affinity (KD between 3-300 nM) that enhance both immune response activation and cancer cell internalization, resolving the contradiction between reliable immune activation and precise binding affinity.
2Reliability
If anti-PD-L1 antibodies are administered to treat cancer, then tumor cells are targeted, but cytotoxicity and internalization efficiency are inadequate
Solution Approach 1:
The patent optimizes the internalization parameter of anti-PD-L1 antibodies through specific CDR amino acid changes. This enhancement in internalization efficiency directly improves cytotoxicity against PD-L1-expressing tumor cells while maintaining reliable tumor targeting, thereby resolving the contradiction between tumor targeting reliability and cytotoxicity productivity.
3Ease of manufacture
If existing immunotherapy treatments are used, then cancer treatment is provided, but survival rates remain low and treatment effectiveness is limited
Solution Approach 1:
The patent enhances the therapeutic effectiveness parameter of anti-PD-L1 antibodies through optimized binding affinity and internalization properties. This improvement in treatment effectiveness directly contributes to better survival rates for cancer patients while maintaining treatment availability, resolving the contradiction between treatment ease of manufacture and survival rate improvement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and ADCs demonstrate enhanced binding affinity, internalization, and cytotoxicity, providing effective treatment options for PD-L1-expressing cancers like melanoma, non-small cell lung cancer, and others, with potential for reduced tumor volume and improved survival outcomes.
Implementation Method 1
Preferred anti-PD-L1 antibodies exhibit a binding affinity to the human PD-L1 protein that is between 3 nM and 300 nM
Implementation Method 2
the antibody further exhibits a total internalization that is higher than the total internalization of Ab1
Data Source
AI summary
Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.